Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (111-120 of 199) with videos related to

Pageof 20
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancerRavi B Parikh, Angel M Cronin, David E Kozono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2011
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard, Yelena Y Janjigian, Maria E Arcila, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II TrialOliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in OncologyLaurent Dercle, Dana E Connors, Ying Tang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2021
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scansLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Xiaoyun Liao, Lynette M Sholl, et al.
European Radiology|September 30, 2020
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trialFiras S Ahmed, Laurent Dercle, Gregory V Goldmacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialMasahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
False-Positive Plasma Genotyping Due to Clonal HematopoiesisYuebi Hu, Bryan C Ulrich, Julianna Supplee, et al.
Pageof 20

Showing results (111-120 of 199) with videos related to

Sort By:
Pageof 20
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancerRavi B Parikh, Angel M Cronin, David E Kozono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2011
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard, Yelena Y Janjigian, Maria E Arcila, et al.
JCO Precision Oncology|May 18, 2022
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific RelapseIbiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II TrialOliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
JCO Clinical Cancer Informatics|January 18, 2019
Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in OncologyLaurent Dercle, Dana E Connors, Ying Tang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2021
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scansLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung CancerAntonio Calles, Xiaoyun Liao, Lynette M Sholl, et al.
European Radiology|September 30, 2020
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trialFiras S Ahmed, Laurent Dercle, Gregory V Goldmacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialMasahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
False-Positive Plasma Genotyping Due to Clonal HematopoiesisYuebi Hu, Bryan C Ulrich, Julianna Supplee, et al.
Pageof 20